China
Africa
Explore chapters and articles related to this topic
Prednisolone Acetate
Published in Anton C. de Groot, Monographs in Contact Allergy, 2021
In Leuven, Belgium, between 1990 and 2017, 16,065 patients were investigated for contact allergy and 118 (0.7%) showed positive patch test reactions to topical ophthalmic medications and/or to their ingredients. Eighty-four individuals (71%) reacted to an active principle. Prednisolone acetate was tested in 57 patients and was the allergen in eye medications in 4. There were no reactions to prednisolone acetate in other types of medications (2).
Laser Surgery in the Treatment of Glaucoma
Published in Neil T. Choplin, Carlo E. Traverso, Atlas of Glaucoma, 2014
The eye is patched shut until the postoperative day 1 examination. At this time, prednisolone acetate 1% is started at 4–8 times per day based on induced inflammation. Atropine 1% is used twice daily for cycloplegia. The ocular hypotensive medications are adjusted, based on clinical response, and the patient asked to return in 1 week and 1 month postoperatively. Eyes may be retreated with decreased numbers of spots if the pressure is not adequately controlled at 4–6 weeks postoperatively.
Endoscopic Lysis of Lumbar Epidural Adhesions
Published in Mark V. Boswell, B. Eliot Cole, Weiner's Pain Management, 2005
Laxmaiah Manchikanti, Vijay Singh
Cousins124 also reports similar complication as above.123 He reports a potential complication of particulate depo-corticosteroids related to inadvertent intravascular administration, producing occlusion of small end arteries, which resulted in visual defects in one case and hearing loss in another case, involving suboccipital nerve block. It is felt that prednisolone acetate tends to form aggregates of the steroid material when mixed with local anesthetic and may pose more of a risk for this problem than other depo-steroids.
Bilateral Acute Depigmentation of Iris (BADI) and Bilateral Acute Iris Transillumination (BAIT)Following Acute COVID-19 Infection
Published in Ocular Immunology and Inflammation, 2023
Cigdem Altan, Berna Basarir, Serife Bayraktar, Ilknur Tugal-Tutkun
In patients who had resolution of pigment dispersion during follow-up, resolution time was recorded. Retinal nerve fiber layer (RNFL) thickness via spectral-domain optical coherence tomography (Spectralis; Heidelberg Engineering, Dossenheim, Heidelberg, Germany) and visual field static automated perimetry, using the 30–2 Swedish Interactive Threshold Algorithm (SITA) standard program (Humphrey Visual Field Analyzer; Carl Zeiss-Meditec Inc., Dublin, CA) findings were recorded. Patients were treated with topical prednisolone acetate 1% when they had acute symptoms or ongoing high-grade pigment dispersion in the anterior chamber and the dose was reduced according to the severity of the signs. In patients with an IOP equal or higher than 24 mmHg, topical antiglaucomatous medications (Dorzolamide/timolol fixed combination or brinzolamide/timolol fixed combination and/or topical brimonidine twice a day and prostaglandin analogs as a last option) and oral asetazolamid were used if needed. The highest IOP during follow-up and total follow-up time were recorded. Glaucoma surgery was carried out in patients with high IOP under maximum antiglaucomatous medication and/or progressive optic nerve head cupping. Topical tobramycin was used in the postoperative one-week period. Clinical findings after glaucoma surgery were also recorded.
Epidemic Retinitis with Positive or Negative Weil Felix Test - a Comparative Study and Outcome with Doxycycline
Published in Ocular Immunology and Inflammation, 2022
Ankush Kawali, Padmamalini Mahendradas, Srinivasan Sanjay, Ashwin Mohan, Bhujang Shetty
Treatment outcomes were studied for groups A and B (Table 2). Group A included 10 eyes of 8 patients and group B included 19 eyes of 15 patients. Mean CDVA at the presentation was 20/160 in both the groups (Range: 20/30 - 20/2000). (p = .839) All the patients received oral doxycycline 100 mg twice a day for 3–4 weeks. Topical prednisolone acetate 1% 4 times/day in tapering dose were given for 4 and 6 eyes in group A and B, respectively. Topical nepafenac 0.1% was given for 8 and 7 eyes in groups A and B, respectively. None of the patients received systemic, periocular, or intraocular steroids or anti-VEGF. Mean thickness of macular edema was 759.2 µm (range: 496–1097 µm) in group A and 776.5 µm (range: 409–1240 µm) in group B at the presentation. (p = .875) Mean duration of complete resolution of macular edema was 41.3 days (range: 30–60 days) and 43.68 days (range: 20–105 days) for groups A and B, respectively. (p = .668) Mean duration of resolution of retinitis lesions were 34.3 days (range: 14–65 days) and 34 days (range: 12–60 days) for group A and B, respectively. (p = .875) Mean CDVA improved to 20/30 in both the groups at the resolution (Range: 20/20 - 20/40 in group A and 20/20 - 20/160 in group B). (p = .456)
Immune Checkpoint Inhibitor-Induced Uveitis
Published in Ocular Immunology and Inflammation, 2020
Emmett T. Cunningham, Ramana S. Moorthy, Manfred Zierhut
Parikh et al.8 described eight consecutive patients with ocular IRAEs seen following treatment with ICIs and other chemotherapeutic agents at a tertiary referral center in Baltimore, Maryland, between November 2017 and June 2019. The cohort included six women and two men, ranging in age from 45 to 74 years, with a median of 69 years and mean of 65.5 years. Three subjects had non-small cell lung cancer, two had melanoma, and one each had prostate cancer and rectal adenocarcinoma. Four of the eight patients received ICIs, including three cases with nivolumab, one with durvalumab, and one with combined therapy with nivolumab and crizotinib (a protein kinase inhibitor). Two of the four subjects had bilateral anterior uveitis, one had combined bilateral anterior and intermediate uveitis associate with granulomatous keratic precipitates, and the fourth had bilateral optic disc edema. Intraocular inflammation responded to topical 1% prednisolone acetate in each case. The optic disc edema resolved following discontinuation of combined ipilimumab and nivolumab following the development of autoimmune hepatitis. The authors noted that in their small series, intraocular inflammation tended to be mild and could be controlled with topical corticosteroids.